GEODON

This brand name is authorized in United States. It is also authorized in Brazil, Cyprus, Ireland, Israel, Mexico, South Africa.

Active ingredients

The drug GEODON contains one active pharmaceutical ingredient (API):

1	Ziprasidone UNII 216X081ORU - ZIPRASIDONE HYDROCHLORIDE
	Ziprasidone has been shown to be an antagonist at both serotonin type 2A (5HT2A) and dopamine type 2 (D2) receptors. It is proposed that the therapeutic activity is mediated, in part, through this combination of antagonist activities. Ziprasidone is also a potent antagonist at 5HT2C and 5HT1D receptors, a potent agonist at the 5HT1A receptor and inhibits neuronal reuptake of norepinephrine and serotonin.
	Read more about Ziprasidone

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
GEODON Powder for solution for injection	MPI, EU: SmPC	Web Search
GEODON Capsule, hard	MPI, EU: SmPC	Health Products Regulatory Authority (IE)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N05AE04	Ziprasidone	N Nervous system → N05 Psycholeptics → N05A Antipsychotics → N05AE Indole derivatives
Discover more medicines within N05AE04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	552820050066817, 552820050066917, 552820050067017, 552820050067117
IE	Health Products Regulatory Authority	36016, 36017, 36018, 39567, 55525, 56729, 73336
IL	מִשְׂרַד הַבְּרִיאוּת	4500, 4502, 4504, 4506
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	318M2001, 346M2002
US	FDA, National Drug Code	0049-0052, 0049-0054, 0049-0056, 0049-0058, 0049-1203, 0049-3920, 0049-3960, 0049-3980, 0049-3990, 50090-4540, 70518-1373
ZA	Health Products Regulatory Authority	32/2.6.5/0584, 32/2.6.5/0585, 32/2.6.5/0586, 32/2.6.5/0587